Vor Bio used its J.P. Morgan Healthcare Conference 2026 presentation to announce a strategic pivot to autoimmune diseases, shifting focus from cell therapy to telitacicept, a dual BAFF/APRIL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results